Which company's drug is Veentuzumab/Ennosumab?

Enfortumab/Enfortumab is an innovative anti-cancer drug developed and originally marketed by Astellas Pharma, a large Japanese pharmaceutical company. Astellas has strong R&D capabilities in the global pharmaceutical field, especially in the treatment of urological tumors and immuno-oncology. The research and development background of veentuzumab is based on the demand for precise treatment of urothelial cancer (especially locally advanced or metastatic bladder cancer). Its drug design combines the concepts of targeted therapy and immunotherapy, aiming to provide new treatment options for patients who have progressed after previous chemotherapy or PD-1/PD-L1 inhibitor treatment.

As an innovative drug owned by Astellas, veentuzumab has completed clinical trials and marketing registration in many countries and regions around the world. Its development process fully reflects the research and development strategies of multinational pharmaceutical companies in the field of rare cancers and refractory tumors. Domestically, original drugs have been approved for marketing, but because innovative drugs are priced higher and have not yet been fully included in medical insurance, patients still need to pay attention to price and accessibility issues when using them. In overseas markets, the price of the original drug of veentuzumab varies due to exchange rates and policies, but it is usually positioned as a high-end targeted anti-cancer drug and is suitable for patients who have failed previous standard treatments.

Overall, veentuzumab, as an innovative R&D result of Astellas, not only reflects the company's technical strength in the field of precision cancer medicine, but also provides an important new treatment option for patients with advanced urinary system tumors. In clinical practice, the application of this drug needs to be carried out under the guidance of a doctor, and a treatment plan should be formulated based on the patient's specific condition and previous treatment history to maximize the effect.

Reference: https://www.padcev.com/